title: [Retrospective analysis of the safety of four hours administration of liposomal amphotericin B in patients with chronic necrotizing pulmonary aspergillosis].
abstract: We have retrospectively analyzed the safety of 4 hours administration of liposomal amphotericin B (L-AMB) compared to less than or equal to 3 hours administration in patients with chronic necrotizing pulmonary aspergillosis (CNPA). The elevation of serum creatinine in the group with 4 hours administration of L-AMB in patients with CNPA was equal to the group with shorter administration time (less than or equal to three hours). During the administration of L-AMB, the group with 4 hours administration of LAMB had significantly a safer profile in relation to hypokalemia during L-AMB treatment than the group with shorter administration time. Additionally, white cell counts, platelet counts, serum creatinine, AST, ALT were not significantly different between L-AMB 4 hours administration group and less than or equal to 3 hours administration group. As the group with 4 hours administration of L-AMB had significantly a safer profile in relation to hypokalemia during L-AMB treatment, this modality can be one of the safer ways in the treatment of CNPA. As L-AMB is one of the fungicidal agents, 4 hours administration of L-AMB can be an optimal way of treating CNPA.
authors.affiliation: Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yatera
authors.forename: Kei
authors.initials: K
authors.lastname: Yamasaki
authors.forename: Minako
authors.initials: M
authors.lastname: Kozaki
authors.forename: Makiko
authors.initials: M
authors.lastname: Shimauchi
authors.forename: Toshinori
authors.initials: T
authors.lastname: Kawanami
authors.forename: Shuya
authors.initials: S
authors.lastname: Nagata
authors.forename: Yu
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Susumu
authors.initials: S
authors.lastname: Tokuyama
authors.forename: Naomasa
authors.initials: N
authors.lastname: Inoue
authors.forename: Chinatsu
authors.initials: C
authors.lastname: Nishida
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ishimoto
authors.forename: Tatsunori
authors.initials: T
authors.lastname: Kawajiri
authors.forename: Yukikazu
authors.initials: Y
authors.lastname: Awaya
authors.forename: Toru
authors.initials: T
authors.lastname: Tsuda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mukae
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced / Q000517:prevention & control; D007262:Infusions, Intravenous; D055744:Invasive Pulmonary Aspergillosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: C068538:liposomal amphotericin B; D000666:Amphotericin B; D011188:Potassium